Compare Eli Lilly And Co (LLY) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Sprott Uranium Miners ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Sprott Uranium Miners ETF trades at $46.5 (market cap $1.87B). The key difference: Eli Lilly And Co is far larger — about 556.1× Sprott Uranium Miners ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Sprott Uranium Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Sprott Uranium Miners ETF for 61 Days on average.
| LLY | URNM | |
|---|---|---|
Market Cap | $1.04T | $1.87B |
Volume | 3,064,878 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $1.28K | $83.99 |
52-Week Low | $799.57 | $46.09 |
Typical Hold Time | 93 Days | 61 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
URNM (Sprott Uranium Miners ETF) trades at $46.09, down 3.72% today amid bearish technical signals. The ETF shows strong fundamental support from uranium's supply-demand imbalance and growing AI energy demand. Recent news highlights nuclear energy's resurgence, with uranium prices rising 21.25% over the past year according to Sprott Asset Management data from August 2026.
Long-term outlook remains positive due to structural uranium deficits and government nuclear investments, but short-term technical weakness and ETF volatility present near-term risks. The convergence of AI power demand and nuclear expansion creates substantial growth potential for uranium miners over the next decade.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
